Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Uses of MRD in patients with multiple myeloma

In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be used in the treatment of multiple myeloma (MM), including how his practice uses MRD. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.